La cadena de opciones muestra datos clave de las opciones de acciones de Virpax Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Virpax Pharmaceuticals..

Virpax Pharmaceuticals (NASDAQ:VRPX) Bolsa, Cadena de Opciones

Virpax Pharmaceuticals

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals Inc

Macro Economic Events

News

Econ #s

Economics

Retail Sales Ex Gas/Autos (MoM) (Nov) +0.2% vs +0.4%; +0.2% Prior

U.S. President-elect Donald Trump is set to meet Netflix&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) co-CEO Ted Sarandos on Tuesday at Trump&#8217;s Mar-a-Lago resort, Reuters cites familiar sources.
Reuters, citing researcher OpenSecrets said Sarandos has traditionally backed Democratic Party candidates by donating to support them.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42514598/hubspots-ai-powered-tools-set-to-drive-smb-growth-and-crm-innovation-analyst-says" rel="noreferrer noopener">HubSpot To Dominate SMB CRM Space With AI-Driven Platform, Says BofA Analyst</a>
Let us examine the dynamics between the streaming giant and the U.S. government. Netflix co-founder Reed Hastings had <a target="_blank" href="https://www.benzinga.com/news/24/07/39932764/kamala-harris-presidential-campaign-secures-7m-from-netflix-co-founder-reed-hastings" rel="noreferrer noopener">committed a record $7 million</a> to a super PAC backing Vice President Kamala Harris&#8217; presidential campaign.
Hastings&#8217; contribution marks his largest single donation to a candidate. Although initially hesitant to endorse Harris following President Joe Biden&#8217;s withdrawal. This pledge followed Harris&#8217; impressive fundraising momentum.
In July, Netflix reportedly experienced a sharp rise in subscription cancellations after Hastings <a target="_blank" href="https://www.benzinga.com/general/entertainment/24/09/41084606/elon-musk-targets-lopsided-anti-trump-donations-by-netflix-employees-as-cancellations-soare" rel="noreferrer noopener">declared his support for Harris</a>.
Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and SpaceX CEO Elon Musk drew attention to the news, pointing to claims of political donation bias among Netflix employees. Bloomberg columnist Lucas Shaw, citing research firm Antenna, reported that Netflix&#8217;s U.S. cancellation rate nearly tripled after Hastings publicly endorsed Harris.
In 2022, three Democratic senators urged Netflix to reduce smoking and vaping depictions <a target="_blank" href="https://www.benzinga.com/general/entertainment/22/04/26429457/senators-demand-netflix-reduce-scenes-with-smoking-vaping" rel="noreferrer noopener">in its streaming content</a>.&nbsp;&nbsp;
Sens. Ed Markey (D-MA), Chris Van Hollen (D-MD), and Richard Blumenthal (D-CT) wrote to Netflix co-CEOs Reed Hastings and Ted Sarandos, requesting fewer scenes featuring smoking and vaping in shows and films.
The senators referenced a Truth Initiative report, which found that Netflix&#8217;s content—popular among young audiences—has shown more smoking or vaping scenes than any other channel over the past four years.
Shows like The Queen&#8217;s Gambit and The Umbrella Academy were cited for having over 200 instances of smoking or vaping in their respective 2020 seasons.
Last week, Trump shared plans to meet with Amazon.com Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) founder Jeff Bezos.
Netflix stock surged 96% year-to-date, backed by its diverse content and live events, including the highly expected&nbsp;NFL Christmas Day games. Oppenheimer&#8217;s Jason Helfstein hailed Netflix as the sole investable <a target="_blank" href="https://www.benzinga.com/general/sports/24/12/42512587/netflix-analyst-say-its-only-investable-media-stock-projects-150-million-nfl-christmas-day-boost" rel="noreferrer noopener">mainstream media stock</a>. The analyst flagged a $2.2 billion advertising opportunity annually for live events.
Price Action: NFLX stock traded lower by 0.11% to $920.04 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42514450/grindrs-expanding-lgbtq-market-and-20-revenue-growth-impresses-goldman-sachs" target="_blank" rel="noreferrer noopener">Grindr&#8217;s Expanding LGBTQ+ Market and 20% Revenue Growth Impresses Goldman Sachs</a></li>
</ul>
Image via Shutterstock

Government

Tech

Media

AMZN

NFLX

TSLA

Trump and Netflix Boss Sarandos Set for High-Stakes Mar-a-Lago Meeting

USA Retail Sales (MoM) For November +0.7% Vs 0.6% Est.; 0.5% Prior

Macro Notification

General

US Core Retail Sales (MoM) (Nov)	+0.2% vs +0.4% Est.; +0.2% Prior

In the current market session, Plains GP Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAGP#NASDAQ">PAGP</a>) stock price is at $18.80, after a 0.21% drop. However, over the past month, the company's stock increased by 1.45%, and in the past year, by 19.09%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734442210_0.png" alt="Past Year Chart" />

<h3>Plains GP Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 29.59 in the Oil, Gas &amp; Consumable Fuels industry, Plains GP Holdings Inc. has a lower P/E ratio of 22.43. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734442210_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

PAGP

P/E Ratio Insights for Plains GP Holdings

Wedbush analyst Jay McCanless reiterates GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) from Outperform to Outperform.

Reiteration

Analyst Ratings

Wedbush Reiterates Outperform on GEO Groupto Outperform

WIIM

APCX

AppTech Payments shares are trading higher after the company announced it received a $5 million investment from AFIOS Partners and is restructuring its board by appointing three new directors.

Asset Sales

MHLD

Maiden Holdings Entered Agreement To Sell Its Swedish subsidiaries To Group Of Insurance And Reinsurance Companies, Terms Not Disclosed

Craig-Hallum analyst Jeff Van Rhee upgrades Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) from Hold to Buy and raises the price target from $2 to $6.

Upgrades

Price Target

RMNI

Craig-Hallum Upgrades Rimini Street to Buy, Raises Price Target to $6

RMTI

Rockwell Medical shares are trading higher after the company announced expectations for $10 million in FY25 net sales and entered a purchase agreement with a provider of dialysis products and services.

Barclays analyst Richard Hightower initiates coverage on NNN REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNN#NYSE">NNN</a>) with a Overweight rating and announces Price Target of $48.

Initiation

Barclays Initiates Coverage On NNN REIT with Overweight Rating, Announces Price Target of $48

Amid growing concerns over cryptocurrency volatility,&nbsp;Thomas Peterffy, chairman of&nbsp;Interactive Brokers, has highlighted the potential for a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) crash to significantly impact the stock market in 2025. During an interview with Bloomberg, Peterffy emphasized the risks associated with high leverage levels in the financial system.
What Happened: Peterffy noted that margin balances have been climbing rapidly, with bitcoin being a primary area of margin-based risk-taking due to&nbsp;low fees on bitcoin futures&nbsp;offered by the CME. He warned that a sudden drop in bitcoin&#8217;s value could compel investors to liquidate&nbsp;assets to meet margin calls,&nbsp;potentially leading to bankruptcies and market instability.
&#8220;I am very worried that people overextended themselves,&#8221; Peterffy said.
In October, FINRA margin debt reached&nbsp;its highest level since February&nbsp;2022, approximately&nbsp;$815 billion, according to YCharts&nbsp;data. Peterffy also pointed out that&nbsp;MicroStrategy&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has raised considerable debt to bolster its bitcoin holdings, which could worsen the situation if bitcoin&#8217;s value falls sharply.
Despite Peterffy&#8217;s concerns, bitcoin recently hit record highs above $107,000. 
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42497241/shiba-inu-burn-rate-skyrockets-515-33-will-the-price-increase?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shiba Inu Burn Rate Skyrockets 515.33%</a>
Why It Matters: The potential for a bitcoin crash has been a topic of discussion among analysts. According to&nbsp;Bernstein analysts, the<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42415888/bitcoin-crashing-mundane-reasons-says-bernstein-buy-the-dip"> recent pullback in bitcoin&#8217;s price </a>below $95,000 was attributed to routine leverage adjustments rather than fundamental issues, suggesting investors should &#8220;buy the dip.&#8221; Despite this, the volatility has raised concerns among traders.
Additionally, a&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42438664/what-bitcoin-crash-dont-think-were-anywhere-near-a-top-analyst-reassures">crypto analyst&nbsp;reassured</a> investors that the current bull run might still have room for growth, despite recent market turbulence. The analysis highlighted that the market is not near a top, indicating potential for further gains. These differing perspectives underscore the uncertainty surrounding bitcoin&#8217;s future trajectory and its potential impact on broader financial markets.
Price Action: As per <a href="https://pro.benzinga.com">Benzinga Pro</a>, Bitcoin was trading at $1,06,955.20 at 8:13 am ET on Tuesday. Meanwhile, SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which tracks the S&amp;P 500 closely was slightly down by 0.38% and Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) had dropped by 0.27%.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42499232/schiffs-advice-to-biden-dogecoins-potential-surge-microsofts-bitcoin-proposal-and-more-this-week-in-crypto?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Schiff&#8217;s Advice To Biden, Dogecoin&#8217;s Potential Surge, Microsoft&#8217;s Bitcoin Proposal, And More: This Week In Crypto</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Bitcoin Crash Could Trigger Stock Market Decline In 2025, Warns Expert: 'I'm Very Worried That People Overextended Themselves'

LICN

Lichen China To Launch AI Large-Scale Model Co-Developed With JD Technology, Trial Operations Set For Late December

TNXP

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Wedbush analyst Richard Anderson initiates coverage on Center (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSR#NYSE">CSR</a>) with a Neutral rating and announces Price Target of $72.

Wedbush Initiates Coverage On Center with Neutral Rating, Announces Price Target of $72

Craig-Hallum analyst Matt Hewitt initiates coverage on Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) with a Buy rating and announces Price Target of $6.

CLOV

Craig-Hallum Initiates Coverage On Clover Health Investments with Buy Rating, Announces Price Target of $6

QIPT

Quipt Home Medical shares are trading lower after the company reported worse-than-expected Q4 sales results.

EVgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) shares are trading lower in premarket trading following the announcement of the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42527145/evgo-inc-announces-pricing-of-secondary-offering-of-class-a-common-stock" rel="noreferrer noopener">pricing of a secondary public offering</a>.
The previously announced offering by EVgo Holdings, an affiliate of LS Power Equity Partners IV, involves 23 million shares of EVgo&#8217;s Class A common stock priced at $5.00 per share.
Additionally, LS Power has granted underwriters a 30-day option to purchase up to <a target="_blank" href="https://www.benzinga.com//node/42517779" rel="noreferrer noopener">3.45 million more shares at the same price.</a>
Notably, EVgo itself is not selling any shares, and the company will not receive any proceeds from the offering. Instead, all funds raised will go to LS Power.
The offering is expected to close on December 18, 2024, pending standard closing conditions. J.P. Morgan, Goldman Sachs, Morgan Stanley, and Evercore ISI are leading the offering, with several other financial institutions involved.
Also Read:<a target="_blank" href="https://www.benzinga.com/24/12/42482968/evgo-125b-holiday-gift-propels-it-to-jpmorgans-top-pick-list" rel="noreferrer noopener"> EVgo: $1.25B &#8216;Holiday Gift&#8217; Propels It To JPMorgan&#8217;s Top Pick List</a>
Recently, EVgo announced the closure of a $1.25 billion guaranteed loan facility from the U.S.<a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/12/42481436/evgo-closes-1-25-billion-loan-from-government-to-expand-fast-charging-network-stock-gains" rel="noreferrer noopener"> Department of Energy&#8217;s Loan Programs Office.</a>
This loan is part of the DOE&#8217;s Title 17 Clean Energy Financing Program and is designed to support EVgo&#8217;s ambitious plans to expand its public electric vehicle (EV) charging infrastructure.
The company aims to build 7,500 new fast charging stalls across the U.S., increasing its network to at least 10,000 stalls by 2029.
This expansion will more than triple EVgo&#8217;s network footprint, positioning it as a leader in supporting the country&#8217;s transportation electrification efforts.
Price Action: EVGO stock is down 22.5% at $4.898 premarket at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42525257/analyst-hikes-teslas-price-target-to-515-musk-expresses-hope-for-stock-to-touch-69042" target="_blank" rel="noreferrer noopener">Elon Musk Hopes TSLA Stock Will Reach $690 As Analysts Raise Price Target Despite Technical Indicators Flashing Warning Signals</a></li>
</ul>
Image: Courtesy of EVgo, Inc.

Equities

Offerings

Movers

EVGO

Why Is Fast Charging Network EVgo Stock Plunging Today?

Biotech

IMMP

Immutep Reports Initial Safety Data For IMP761, The First LAG-3 Agonist, In Phase I Trial With No Treatment-Related Adverse Events; Additional Data Expected In H1 2025 To Support Autoimmune Disease Treatment Potential

On Tuesday, ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) and tier-one automotive supplier Denso Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DNZOF#OTC">DNZOF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DNZOY#OTC">DNZOY</a>) announced that they are strengthening their long-term relationship to support the procurement of autonomous driving (AD) and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42522062/onsemi-and-denso-collaborate-for-a-strengthened-relationship" rel="noreferrer noopener">advanced driver assistance systems (ADAS) technologies</a>.
ON Semiconductor has supplied Denso with the latest intelligent automotive sensors to enhance ADAS and AD performance for over a decade.
These semiconductors have become increasingly vital in improving vehicle intelligence, including connectivity, to help reduce traffic accident fatalities.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42520765/super-micro-drops-below-50-day-average-faces-nasdaq-100-removal-just-months-after-entry" rel="noreferrer noopener">Super Micro Drops Below 50-Day Average, Faces Nasdaq 100 Removal Just Months After Entry</a>
Denso President Shinnosuke Hayashi emphasized the importance of a strong supply chain for critical materials like semiconductors, noting that Denso, the world&#8217;s second-largest supplier of automotive systems and parts, relies on this to deliver innovative products to customers.
He highlighted the need for collaboration with industry leaders like ON Semiconductor, which has advanced vehicle safety and autonomy through intelligent sensing technologies while providing reliable supply assurance.
Denso intends to acquire ON Semiconductor stock on the open market as a mark of their collaboration.
Bank of America analyst Vivek Arya identified ON Semiconductor among his top picks for 2025, projecting a <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42516826/nvidia-and-5-other-stocks-are-analysts-top-semiconductor-picks-for-2025-sees-2-ai-trends" rel="noreferrer noopener">recovery from cyclical trends</a>. He expects the automotive and industrial sectors to drive significant semiconductor demand in the latter half of the year.
Arya anticipates that in the first half of 2025, investments in artificial intelligence (AI) will continue to surge, driven by AI training and model scaling. He notes that cloud customers will likely accelerate the deployment of Nvidia Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell architecture during this period.
Regarding the CHIPS Act, Arya expects the legislation, enacted under President Joe Biden, to remain in effect following President-elect Donald Trump&#8217;s inauguration. He projects that the remaining funding will be distributed in 2025, substantially supporting the U.S. semiconductor industry.
After ON Semiconductor&#8217;s <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41603256/on-semiconductors-q3-solid-analyst-highlight-l-shaped-recovery" rel="noreferrer noopener">third-quarter print</a>, Needham analyst Quinn Bolton projected an L-shaped recovery for the company through the first half of 2025. Datacenter opportunities will gain traction as key design wins ramp up next year.
Goldman Sachs analyst Toshiya Hari, Benchmark analyst David Williams, and JP Morgan analyst Harlan Sur flagged China&#8217;s EV market strength and silicon carbide (SiC) growth.
Investors can gain exposure to stocks of companies that manufacture semiconductors through the VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>).
Price Action: ON stock closed higher by 0.72% at $66.44 on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514620/googles-veo-2-and-imagen-3-set-new-standards-for-ai-creativity" target="_blank" rel="noreferrer noopener">Google&#8217;s Sora Rival &#8211; DeepMind Introduces New Video Generation Tool</a></li>
</ul>

DNZOF

DNZOY

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

ON Semiconductor and Denso Team Up to Boost Self-Driving Tech

Virpax Pharmaceuticals ( ($VRPX) ) just unveiled an update. Virpax Pharmaceuticals has been notified by Nasdaq of not meeting the minimum bid price...

Virpax Pharmaceuticals Faces Nasdaq Delisting Risk

Warning: VRPX is at high risk of performing badly

Adial Pharmaceuticals (ADIL) announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Most re...

Adial Pharmaceuticals appoints Shah as Chief Financial Officer

The latest announcement is out from Virpax Pharmaceuticals ( ($VRPX) ). Virpax Pharmaceuticals has announced a $5 million public offering of common...

Virpax Pharmaceuticals Announces $5M Public Offering

An announcement from Virpax Pharmaceuticals ( ($VRPX) ) is now available. Virpax Pharmaceuticals has appointed Usama Chaudhry as Chief Financial Of...

Virpax Pharmaceuticals Announces New Chief Financial Officer

Virpax Pharmaceuticals (VRPX) announced that it has been granted an extension of its cooperative research and development agreement with the Nation...

Virpax Pharmaceuticals announces HHS pact over NES100 developmental extension

Virpax Pharmaceuticals (VRPX) announced results from a minipig dose range finding, or DRF, study for Probudur. Probudur is the company's long-actin...

Virpax Pharmaceuticals announces results from Probudur minipig DRF study

Virpax Pharmaceuticals ( ($VRPX) ) has issued an update. Virpax Pharmaceuticals, Inc. has taken significant steps to enhance its governance and str...

Virpax Pharmaceuticals Strengthens Leadership and Expands Collaborations

Palladyne AI Corp., SKK Holdings Ltd., and Virpax Pharmaceuticals are the 3&nbsp;Penny Stocks&nbsp;to watch on November 26, 2024, based on&nbsp;Tip...

3 Penny Stocks to Watch Now, 11/26/24

An announcement from Virpax Pharmaceuticals ( ($VRPX) ) is now available. Virpax Pharmaceuticals announced the resignation of Mr. Gary Herman from ...

Virpax Pharmaceuticals Announces Board Member Resignation

ADIL

PDYN

VRPX

Press Releases

Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™

Virpax Regains Compliance with Nasdaq Minimum Bid Price

Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments

Management

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Virpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Virpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public Offering

Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative

Comments

Virpax Pharmaceuticals

Virpax Pharmaceuticals (VRPX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL